// App-Quantinova.ai

651 : A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.

Researchers

Presenter

  • Donald A. Richards

Principal Investigators

  • Fadi S. Braiteh

  • A. A. Garcia

  • David A. Smith

  • Charlotte Fenton McDonagh

  • Kate-Lyn Kawash

  • Sasha Frye

  • William Jeffery Edenfield

  • Stephen Patrick Anthony

  • Beth A. Hellerstedt

  • Robert N. Raju

  • Carlos Becerra

  • Wael A. Harb

Medical Centers

  • Merrimack Pharmaceuticals, Cambridge, MA

  • Northwest Cancer Specialists PC, Vancouver, WA

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • Horizon Oncology Center, Lafayette, IN

  • GHS Institute of Transitional Oncology Research, Greenville, SCUniversity of Southern California, Los Angeles, CAFox Chase Cancer Center, Philadelphia, PA

  • Evergreen Hematology and Oncology/US Oncology Research Affliate, Spokane, WA

  • US Oncology Phase II Group, Virginia Oncology Associates, Norfolk, VA

  • Tyler Cancer Center, US Oncology Research, McKesson Specialty Health, Houston, TX

  • US Oncology Research, LLC, McKesson Specialty Health, and Texas Oncology, Central Austin Cancer Center, Austin, TX

  • Merrimack Pharmaceuticals, Cambridge, MA

  • Kettering Medical Center Health Network, Kettering, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Erb-B2 Receptor Tyrosine Kinase 3

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • MM 111

Outcome

  • Positive

Study Design

  • pharmacokinetics

Phase

  • I

Study Id's

  • NCT01304784

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved